Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07292298 · ClinicalTrials.gov registry record · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
A Phase 2 study of Rectal Cancer and Rectal Adenocarcinoma, sponsored by University of Colorado, Denver.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 44
- Enrollment target
- 3
- Study locations
NCT07292298: Recruiting Phase 2 study of Rectal Cancer and Rectal Adenocarcinoma, sponsored by University of Colorado, Denver.
NCT07292298 is a Phase 2 study of Rectal Cancer and Rectal Adenocarcinoma that is actively recruiting participants, run by University of Colorado, Denver. The registered enrollment target is 44 participants, below the 3,166-participant average among 70 other Rectal Cancer trials with a reported enrollment target (99% lower). The trial reports 3 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07292298, a Phase 2 study of Rectal Cancer and Rectal Adenocarcinoma, is actively recruiting participants, sponsored by University of Colorado, Denver.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 44 participants
- Enrollment target
- 3
- Study locations
Study Summary
Rectal cancer patients who do not achieve a complete response to standard of care chemotherapy and radiation often require surgical resection as part of curative intent therapy. This study will evaluate whether additional "focal" radiation delivered internally (rectal brachytherapy) can provide complete responses and thus spare the requirement for surgery. The main questions are whether: 1) rectal brachytherapy is safe in this clinical treatment paradigm and if 2) rectal brachytherapy improves organ preservation (no need for surgery). The trial involves an additional MRI pelvis and sigmoidoscopy with marker placement to define high-risk residual disease for radiation planning. Subsequently, 3 outpatient brachytherapy treatments are given on a weekly basis. If a patient achieves a complete response to brachytherapy, standard of care non-operative surveillance visits are conducted with study visits aligned during the first two years following brachytherapy.
Primary Outcome
As evaluated by standard of care sigmoidoscopy and MRI
Conditions Studied
Interventions
- RADIATION High Rare Dose Rectal Brachytherapy Boost
Study Locations (3)
Colorado
- University of Colorado Cancer Center - Aurora
New York
- University of Rochester Medical Center - Rochester
Oregon
- Oregon Health and Sciences University - Portland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 44 participants |
| Start Date | 2026-11 |
| Est. Completion | 2031-11 |
| Phase | Phase 2 |
What NCT07292298 shows while recruiting
NCT07292298 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 44 participants, a relatively small participant target, below the 3,166-participant average among 70 other Rectal Cancer trials with a reported enrollment target (99% lower).
The record links to 2 conditions, with Rectal Cancer appearing as the primary indexed condition, and to 1 intervention - of which High Rare Dose Rectal Brachytherapy Boost is the first listed.
NCT07292298 reports a single indexed study location in Colorado, New York, Oregon.
Frequently Asked Questions
What is clinical trial NCT07292298 about?
NCT07292298 is a clinical study titled "Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates". Rectal cancer patients who do not achieve a complete response to standard of care chemotherapy and radiation often require surgical resection as part of curative intent therapy. This study will evaluate whether additional "focal" radiation delivered internally (rectal brachytherapy) can provide comp...
What is the current status of trial NCT07292298?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 44 participants. The study started on 2026-11. Estimated completion is 2031-11.
What conditions does trial NCT07292298 study?
This clinical trial studies the following conditions: Rectal Cancer, Rectal Adenocarcinoma.
What interventions are being tested in trial NCT07292298?
The interventions under investigation include: High Rare Dose Rectal Brachytherapy Boost (RADIATION).
Who is sponsoring clinical trial NCT07292298?
This trial is sponsored by University of Colorado, Denver, which has 1,283 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07292298 being conducted?
This trial has 3 study locations across Colorado, New York, Oregon. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Rectal Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07292298's enrollment target sits among peer trials
44 45th of 70 higher than 26 of 70 other Rectal Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Rectal Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Phase I-II Study to Test the Safety and Efficacy of PD1 (AB122) and Adenosine Receptor (AB928) Antagonists With Chemotherapy After Short-Course Radiation for Rectal Cancer.
RECRUITING · Phase 2
-
Trial of the Efficacy and Safety of Short and Long Course Radiation Therapy With/Without BMX-001
RECRUITING · Phase 2
-
A Study of Fruquintinib Plus FOLFIRI as Second-Line Treatment for Participants With Metastatic Colorectal Cancer (mCRC)
RECRUITING · Phase 2
-
Watchful Waiting for Complete Responders to Therapy in Rectal Cancer
RECRUITING · Phase 2
-
Total Neoadjuvant Therapy With mFOLFOX and Short-course Radiation in Resectable Rectal Cancer
RECRUITING · Phase 2
-
Sequential TAS-OX Alternating With TAS-IRI Plus Bevacizumab for Late-Line Metastatic Colorectal Cancer
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02323945 · 44 participants · NA
Effects of Breathing Mild Bouts of Low Oxygen on Limb Mobility After Spinal Injury
- NCT03093909 · 44 participants · Phase 1
Study of Aerosol Gemcitabine in Patients With Solid Tumors and Pulmonary Metastases
- NCT03104491 · 44 participants · Phase 1
Inotuzumab Ozogamicin Post-Transplant For Acute Lymphocytic Leukemia
- NCT03781765 · 44 participants · Phase 4
Stimulant vs. Non-stimulant Treatments and Reward Processing in Drug-naive Youth at SUD Risk
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia